NATICK, Mass., Jan. 8, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced that it has been awarded a grant from the National Multiple Sclerosis (MS) Society through its affiliate, Fast Forward, to support research on the potential of SINE compounds in inflammatory models of disease, including MS. Finding ways to restore and protect the damaged nervous system is a key priority of the National MS Society’s No Opportunity Wasted (NOW) research campaign to ultimately eradicate MS.
Help employers find you! Check out all the jobs and post your resume.
